FUJIFILM Biotechnologies has been awarded the Most Innovative CDMO (Biologics) at the 2026 CDMO Leadership Awards.
The awards, presented by Outsourced Pharma and Life Science Connect, are based on direct feedback from biopharma sponsors who have collaborated with CDMOs in the past 18 to 24 months.
This recognition is a result of verified evaluations from sponsors, focusing on key performance criteria and minimum qualification standards within each category.
"As part of Fujifilm's 90-year heritage in healthcare innovation, our company continues to invest in science, analytics and process development to support biologics, vaccines and advanced therapies from early development through commercialisation," said Bernie Clark, Vice President, Global Marketing, FUJIFILM Biotechnologies.
Building on our legacy of innovation, we've recently launched ShunzymeX, a technology platform that leverages a novel protease to simplify the purification process of complex biologics.
The recognition is attributed to the company's ongoing investment in scientific research and process development, as well as its collaborative efforts with both industry and academic partners.
"We are very grateful to our partners for their trust. Our success is built on collaboration, transparency and a shared mission to be Partners for Life," added Clark.